Rivaroxaban plasma levels in acute ischemic stroke and intracerebral hemorrhage.
David J SeiffgeGeorg KägiPatrik MichelUrs FischerYannick BéjotSusanne WegenerMarialuisa ZeddeGuillaume TurcCharlotte CordonnierPeter S SandorGilles RodierAndrea ZiniManuel CappellariSabine SchädelinAlexandros A PolymerisDavid WerringSebastian ThilemannIlaria MaestriniEivind BergeChristopher TraenkaJochen VehoffGian Marco De MarchisMonika KapauerNils PetersGaia SirimarcoLeo H BonatiMarcel ArnoldPhilippe A LyrerEmmanuel De MaistreAndreas LuftDimtrios A TsakirisStefan T Engelternull nullPublished in: Annals of neurology (2018)
RivLev did not differ between patients with AIS and ICH. Half of the patients with AIS under rivaroxaban had a RivLev low enough to consider thrombolysis. In ICH patients, two-thirds had a RivLev high enough to meet the eligibility for the use of a specific reversal agent. INR thresholds perform poorly to inform treatment decisions in individual patients. Ann Neurol 2018;83:451-459.